歌禮製藥-B(1672.HK)擬回購最多1.12億股 股價急彈14%越百天線
歌禮製藥-B(1672.HK)擬回購最多1.12億股,該股今天重越百天線,午後升幅曾擴至15%高見4.55元,現造4.51元,回升14%,成交急增至846萬股,涉資3,615萬元。
歌禮昨日公布,董事會擬根據6月6日舉行股東會授予董事會購回股份的一般授權行使其權力,在合適時間於公開市場回購最多約1.12億股,相當於股東周年會日已發總股數10%。董事會認為,公司現時財務狀況穩健,股份成交價未能反映內在價值,建議回購股份及於其後註銷所購回股份可提升其價值,也反映公司對長遠業務前景及增長潛力充滿信心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.